ArticleBMJ (Clinical research ed.)2023
Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance.
Abstract read
In one paragraph
Article in BMJ (Clinical research ed.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- CONSORT 2025 statement: updated guideline for reporting randomized trials: a Korean translation.Ewha medical journal · 2025Guideline
- A First-In-Human Randomized Controlled Phase 1 Study Assessing the Safety and Tolerability of Topical TCP-25 Gel in Epidermal Suction Blister Wounds.Clinical and translational science · 2026Trial
- Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First-in-Human Studies in Healthy Participants and Patients.Clinical pharmacology and therapeutics · 2026Trial
- Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants.Clinical and translational science · 2025Trial
- Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection.Journal of opioid managementTrial
- A systematic review of heterogeneity in clinical trial design for anal cancer radiotherapy-immunotherapy combinations.Clinical and translational radiation oncology · 2026Review
- First-in-Human, Open-label, Single-Arm Phase I Study of [211At] meta-Astatobenzylguanidine in Patients with Pheochromocytoma or Paraganglioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Single Intratympanic Injection of Proprietary Brain-Derived Neurotrophic Factor (OTO-413) in Subjects with Speech-in-Noise Hearing Impairment: a Randomized, Dose Escalating, Double-Blind, Placebo-Controlled Phase 1/2 Study.Journal of the Association for Research in Otolaryngology : JARO · 2026Article
- Reporting of dog-assisted intervention trials: extension of the SPIRIT 2025 and CONSORT 2025 statement.BMC medical research methodology · 2026Article
- Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early-Phase Oncology Drug Development.Clinical pharmacology and therapeutics · 2026Article
- Toxicity outcomes in phase 1 lymphoma trials abstracts are under-reported, with high use of minimizing language.HemaSphere · 2026Article
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Clinical Trial Simulation: Planning With the OCTAVE Framework, Implementation and Validation Principles.Statistics in medicine · 2026Article
- Improving research transparency: An interpretation of the updated consolidated standards of reporting trials 2025 guideline from the perspective of clinical trials in oncology.Cancer pathogenesis and therapy · 2026Article
- Establishing the Median Effective Dose of Tegileridine for Immediate Postoperative Analgesia Following Laparoscopic Colorectal Cancer Surgery: A Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
- Age-Stratified EDDrug design, development and therapy · 2026Article
- Harnessing Dietary Tryptophan: Bridging the Gap Between Neurobiology and Psychiatry in Depression Management.International journal of molecular sciences · 2026Review
- Results of a non-randomized, open-label phase I study evaluating the novel immunomodulatory peptide TCP-25 for treatment of dystrophic epidermolysis bullosa.Orphanet journal of rare diseases · 2025Article
- Pharmacokinetics and Safety of Pelacarsen, a GalNAcClinical and translational science · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Christina YapInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-6715-2514
Olga SolovyevaInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0001-7828-4099
Johann de BonoInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-2034-595X
Jan RekowskiInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-5207-3864
Dhrusti PatelInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0009-0001-4113-2726
Thomas JakiMRC Biostatistics Unit, Cambridge University, Cambridge, UK.ORCID 0000-0002-1096-188X
Adrian ManderCentre For Trials Research, Cardiff University, Heath Park, Cardiff, UK.ORCID 0000-0002-0742-9040
Thomas R Jeffry EvansInstitute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.ORCID 0000-0002-4175-914X
Richard PeckDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.ORCID 0000-0003-1018-9655
Kathryn S HaywardDepartments of Physiotherapy, and Medicine (Royal Melbourne Hospital), University of Melbourne, VIC, Australia.ORCID 0000-0001-5240-3264
Sally HopewellOxford Clinical Research Unit, NDORMS, University of Oxford, Oxford, UK.ORCID 0000-0002-6881-6984
Moreno UrsinoReCAP/F CRIN, INSERM, Paris, France.ORCID 0000-0002-5709-4322
Khadija Rerhou RantellMedicines and Healthcare Products Regulatory Agency, London, UK.ORCID 0000-0002-6747-7650
Melanie CalvertCentre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-1856-837X
Shing LeeColumbia University Mailman School of Public Health, New York, NY, USA.
Andrew KightleyLichfield, UK.ORCID 0000-0002-5228-3255
Deborah AshbySchool of Public Health, Imperial College London, London, UK.ORCID 0000-0003-3146-7466
An-Wen ChanDepartment of Medicine, Women's College Research Institute, University of Toronto, Toronto, ON, Canada.
Elizabeth Garrett-MayerCenter for Research and Analytics, American Society of Clinical Oncology, Alexandria, VA, USA.ORCID 0000-0003-4709-0333
John D IsaacsTranslational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.ORCID 0000-0002-6103-7056
Robert GolubDepartment of Medicine, Northwestern University Feinberg School of Medicine, 633 Clark Street, Evanston, IL, USA.
Olga KholmanskikhFederal Agency for Medicines and Health Products, Brussels, Belgium.
Dawn RichardsClinical Trials Ontario, MaRS Centre, Toronto, ON, Canada.ORCID 0000-0003-1151-0826
Oliver BoixBayer, Berlin, Germany.
James MatchamStrategic Consulting, Cytel (Australia), Perth, WA, Australia.
Lesley SeymourInvestigational New Drug Programme, Canadian Cancer Trials Group, Cancer Research Institute, Queen's University, Kingston, ON, Canada.ORCID 0000-0001-8081-0799
S Percy IvyInvestigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Institute of Health, Bethesda, MD, USA.ORCID 0000-0001-7747-072X
Lynley V MarshallInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-6537-2118
Antoine HommaisDepartment of Clinical Research, National Cancer Institute, Boulogne-Billancourt, France.
Rong LiuBristol Myers Squibb, New York, NY, USA.
Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.ORCID 0000-0002-0807-7139
Jordan BerlinVanderbilt-Ingram Cancer Center, Nashville, TN, USA.ORCID 0000-0001-7571-2385
Aude EspinasseInstitute of Cancer Research, London SM2 5NG, UK.ORCID 0000-0002-1271-302X
Munyaradzi DimairoDivision of Population Health, Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, UK.ORCID 0000-0002-9311-6920
Christopher J WeirEdinburgh Clinical Trials Unit, Usher Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-6494-4903
Funding
Cancer Research UK 11650Cancer Research UK 12946Cancer Research UK 18182Cancer Research UK 20409Cancer Research UK 20850Cancer Research UK 29827Cancer Research UK NACDDP-SEP22/100001Medical Research Council MC_UU_00002/14Medical Research Council MR/N026977/1Medical Research Council MR/S014357/1Medical Research Council MR/T044934/1
Abstract
PubMed holds no abstract for this paper.
Indexed as
ChecklistResearch DesignHumans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.